Verteporfin photodynamic therapy for neovascular age-related ...

48 Results (2) – objectives A, B, C and DTABLE 12 Influence of covariates on baseline BCVA and change in BCVA over timeCovariate Regression coefficient 95% CI p-valueTime (per year) –15.68 –17.78 to –13.59 < 0.0001Time 2 (per year) 3.33 2.74 to 3.92 < 0.0001TAP eligibilityEFT group 0.00 –IFT group 1.42 0.17 to 2.67 0.026% of lesion classified as classic 0.014 b≥ 50% 0.00 – –> 0% and < 50% 1.13 –0.44 to 2.70 0.1580% 3.43 1.04 to 5.83 0.005Unknown % classic 1.50 0.29 to 2.72 0.016% of lesion classified as classic × time a 0.031 b≥ 50% 0.00 – –> 0% and < 50% 2.08 0.38 to 3.77 0.0160% 2.79 0.20 to 5.38 0.035Unknown % classic 0.77 –0.45 to 1.98 0.218Age (year) –0.20 –0.26 to –0.14 < 0.0001Age × time a –0.29 –0.36 to –0.22 < 0.0001Baseline ETDRS 7 (per letter) 0.743 0.70 to 0.77 < 0.0001Baseline ETDRS 7 (per letter) × time a –0.20 –0.23 to –0.16 < 0.0001GenderMale 1.00 – –Female 1.76 0.85 to 2.67 0.0002Smoking status0.091 bNever smoked 1.00 – –Ex-smoker 1.89 0.34 to 3.44 0.017Current smoker 1.59 0.01 to 3.18 0.049Unknown smoking status 2.03 0.10 to 3.96 0.039Smoking status × time a0.002 bNever smoked 1.00 – –Ex-smoker 1.09 –0.66 to 2.83 0.223Current smoker 3.03 1.28 to 4.78 0.0007Unknown smoking status 1.21 –0.78 to 3.20 0.233BCVA in fellow eye< 0.0001 bFellow worse 1.00 – –Fellow similar to treated eye –2.12 –3.46 to –0.77 0.002Fellow better –2.57 –3.73 to –1.40 < 0.0001BCVA in fellow eye x time a< 0.0001 bFellow worse 1.00 – –Fellow similar to treated eye –1.53 –3.04 to –0.02 0.0471Fellow better –5.16 –6.52 to –3.79 < 0.0001CI, confidence interval.a Interactions with time, implying that the rate of change in BCVA over time was influenced by the baseline line covariate.b p-value for overall factor (i.e. across multiple categories).